All Blogs

Mar 12, 2025

Obesity is the second leading cause of preventable death, associated with a range of inflammatory conditions that contribute to cardiovascular disease, diabetes, respiratory problems, mental health issues, hypertension, obstructive sleep apnea, cancer, and high cholesterol. This represents a significant public heal...

Jul 23, 2024

CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The Coalition for Epidemic Preparedness Innovations and Valneva SE have expanded their partnership to enhance access to the world's first chikungunya vaccine, IXCHIQ®, in Low- and Middle-Income Countries (LMICs). CEPI will...

Jul 22, 2024

Conventional  IgA nephropathy treatments include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. The only two FDA-approved treatments for managing IgAN are TARPEYO/KINPEYGO (budesonide) and FILSPARI (sparsentan)....

Jul 19, 2024

After a few days of investor anxiety, Arcutis Biotherapeutics announced that the FDA has approved ZORYVE for a new indication: atopic dermatitis. The FDA was scheduled to announce its decision on ZORYVE (roflumilast) for this new use on the 7th of this month, but the date passed without news. In an uncommon move to...

Jul 18, 2024

Inspira™ Secured Approval From Israeli Authorities for its INSPIRA™ ART100 System On July 11, 2024, Inspira™ Technologies OXY B.H.N. Ltd., a pioneering medical technology company, secured a pivotal milestone with the receipt of the Israeli Ministry of Health's medical devices and accessories ("AMAR") approval fo...

Jul 17, 2024

Vaccines have been one of the most significant advancements in medical science, saving millions of lives by preventing infectious diseases. While the primary component of a vaccine is the antigen that stimulates an immune response, another crucial element often goes unnoticed: the adjuvant.  What are Vaccin...

Jul 16, 2024

Immutep Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell Carcinoma Patients Immutep Limited announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, evaluating eftilagimod alfa (efti) combined with MSD’s anti-PD-1 therapy KEYTR...

Jul 15, 2024

Vyvgart enjoying strong commercial uptake whereas RYSTIGGO is preferred for MuSK+ Myasthenia gravis. What do the physicians believe? The neonatal Fc receptor (FcRn) inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma, along with a few early-stage players ...

Jul 12, 2024

In a strategic move aimed at bolstering its portfolio in inflammatory bowel disease (IBD) treatments, Eli Lilly and Company has announced a definitive agreement to acquire Morphic Holding for approximately USD 3.2 billion. The purchase price represents a 79% premium to Morphic’s closing stock price. Post the tender...

May 08, 2025

Ulcerative colitis is a type of inflammatory bowel disease of unknown origin that targets the lining of the colon. Symptoms typically include diarrhea, abdominal pain, discomfort, and the presence of blood in the stool. The severity of the condition can vary, with inflammation affecting just the rectum, extending t...